Transaction DateRecipientSharesTypePriceValue
6th October 2020John L Lamattina46,388Conversion of derivative$0.00
26th June 2020Thomas Edward Hamilton159,433Other acquisition or disposition$0.00
26th June 2020Carole Ben Maimon25,083Other acquisition or disposition$0.00
26th June 2020Thomas Edward Hamilton133,420Other acquisition or disposition$0.00
26th June 2020Therapeutics Holdings, Llc Chondrial6,091,242Other acquisition or disposition$0.00
10th June 2020John L Lamattina831Grant/award etc.$0.00
15th May 2020Thomas Edward Hamilton200,000Open or private purchase$5.96$1,192,920.00
17th December 2019Robert J Perez2,500Disposition due to a tender of shares in a change of control transaction$114.50$286,250.00
1st August 2019John L Lamattina847Payment by withholding$95.58$80,958.29
1st August 2019John L Lamattina2,500Exercise of derivative$32.30$80,750.00
Zafgen logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.

Zafgen, Inc. is a biopharmaceutical company. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases.

Ticker: ZFGN
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1374690
Employees: 7
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags